{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000076","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.689765+00:00","generated_at":"2026-06-13T22:47:21.851001+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Caribou stockholders elect Guggenhime, Johnson, Whiting as Class II directors and ratify Deloitte as auditor","bullets":["Andrew Guggenhime: 31.0M votes for, 5.3M withheld, 9.4M broker non-votes.","David L. Johnson: 31.8M for, 4.5M withheld, 9.4M broker non-votes.","Nancy Whiting: 31.9M for, 4.5M withheld, 9.4M broker non-votes.","Ratification of Deloitte & Touche as independent auditor: 45.7M for, 51.8K against, 82.4K abstain.","Annual meeting held June 15, 2023; all proposals passed."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000076","json":"https://secwatch.observer/filing/0001619856-23-000076.json","markdown":"https://secwatch.observer/filing/0001619856-23-000076.md","text":"https://secwatch.observer/filing/0001619856-23-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000076/0001619856-23-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000076/crbu-20230615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:47:21.851001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0cfce7bdedd97159144c249de77c2196c8d99c6e","claim":"Caribou Biosciences, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-06-15 meeting.","evidence_excerpt":"Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, by the following votes: Votes For Votes Against Votes Abstain 45,652,597 51,771 82,435","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000076/0001619856-23-000076-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-15"}],"fact_type":"shareholder_vote"},{"claim_id":"d6249a0e5ec8a23458637522e1468c1c876277b4","claim":"Caribou Biosciences, Inc. shareholders approved Election of Two Class I Directors at the 2023-06-15 meeting.","evidence_excerpt":"Proposal 1 - Election of Two Class I Directors Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2026 annual meeting of stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation, or removal. Nominee Votes For Votes Withheld Broker Non-Votes Andrew Guggenhime, M.B.A. 31,032,443 5,325,715 9,428,645 David L. Johnson, M.B.A. 31,840,467 4,517,691 9,428,645 Nancy Whiting, Pharm.D. 31,863,074 4,495,084 9,428,645","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000076/0001619856-23-000076-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}